In a prospectively registered cohort of consecutive IDH-wildtype (IDHwt) GBM patients treated with standard therapy, we retrospectively reviewed radiological data to (1) characterize the progression pattern and (2) identify biological factors that drive distant progression. This evidence concerns the gene IDH1 and glioblastoma.